Lithium inhibits the development of myeloma bone disease in vivo.

Lithium inhibits the development of myeloma bone disease in vivo.

Bibliographic Details
Main Authors:	Edwards, C, Edwards, JR, Esparza, J, Oyajobi, B, McCluskey, B, Munoz, S, Grubbs, B, Mundy, G
Format:	Conference item
Published:	2006

Similar Items

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
by: Edwards, C, et al.
Published: (2008)

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
by: Edwards, C, et al.
Published: (2009)

Advances in the management of myeloma bone disease.
by: Shipman, C, et al.
Published: (2005)

The importance of the bone marrow microenvironment in multiple myeloma; Differential responses to lithium in vivo
by: Edwards, C, et al.
Published: (2006)

Targeting Wnt signaling in myeloma in vivo; Differential effects on tumor burden and myeloma bone disease
by: Edwards, C, et al.
Published: (2007)

Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
by: Edwards, C, et al.
Published: (2007)

Dkk1 modulates osteoclastogenesis and bone resorption: Implications for myeloma bone disease.
by: Oyajobi, B, et al.
Published: (2005)

The pathogenesis of the bone disease of multiple myeloma.
by: Edwards, C, et al.
Published: (2008)

Decreased bone marrow-derived adiponectin contributes to myeloma pathogenesis in vivo
by: Fowler, J, et al.
Published: (2010)

Histone deacetylase 1 (HDAC1) regulates dickkopf 1 (DKK1) expression: Implications for myeloma bone disease.
by: Wideman, C, et al.
Published: (2006)

The ubiquitin-proteasome pathway is dysregulated in myeloma cells in the bone microenvironment in vivo
by: Edwards, C, et al.
Published: (2007)

Increasing adiponectin via an apolipoprotein peptide mimetic, L-4F, increases bone formation in normal mice and prevents myeloma bone disease in vivo
by: Fowler, J, et al.
Published: (2011)

Osteoclasts in Myeloma Are Derived from Gr-1(+)CD11b(+) Myeloid Immune Suppressor Cells of the Bone Marrow Niche in Vivo
by: Zhuang, J, et al.
Published: (2008)

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
by: Gámez, B, et al.
Published: (2021)

Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche
by: Zhuang, J, et al.
Published: (2007)

Myeloma cells decrease EphB4 expression in osteoblasts: A novel mechanism for regulation of bone formation in multiple myeloma
by: Bates, A, et al.
Published: (2007)

Myeloma cells decrease EphB4 expression in osteoblasts; A novel mechanism for regulation of bone formation in multiple myeloma
by: Bates, A, et al.
Published: (2007)

Host Bone Marrow-Derived Stromal Cells Promote Myeloma Initiation and Development of Osteolysis
by: Fowler, J, et al.
Published: (2008)

Host-derived MMP-7 decreases myeloma progression in vivo: An unexpected role for MMP-7 and osteopontin in myeloma pathogenesis
by: Lwin, S, et al.
Published: (2011)

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.
by: Fowler, J, et al.
Published: (2011)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
by: Lwin, S, et al.
Published: (2017)

Novel therapeutic targets in myeloma bone disease.
by: Webb, S, et al.
Published: (2014)

A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease.
by: Ayati, B, et al.
Published: (2010)

Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
by: Hua Wang, et al.
Published: (2018-09-01)

Preventative metformin treatment increases myeloma tumour burden and bone disease in vivo
by: Beatriz Gamez, et al.
Published: (2020-10-01)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
by: Zhuang, J, et al.
Published: (2008)

Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
by: Fowler, J, et al.
Published: (2012)

The Bone Marrow Microenvironment in Multiple Myeloma
by: Edwards, C
Published: (2010)

Tumor-host cell interactions in the bone disease of myeloma.
by: Fowler, J, et al.
Published: (2011)

Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease
by: Gooding, S, et al.
Published: (2019)

Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo.
by: Edwards, J, et al.
Published: (2010)

Cholesterol promotes myeloma cell viability and increases bone marrow myeloma tumour burden in vivo
by: Beatriz Gamez, et al.
Published: (2020-10-01)

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
by: Beatriz Gámez, et al.
Published: (2022-01-01)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
by: Croucher, P, et al.
Published: (2001)

Wnt signaling: bone's defense against myeloma.
by: Edwards, C
Published: (2008)

Bone marrow adiposity and multiple myeloma
by: Morris, E, et al.
Published: (2018)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

BTK inhibition in myeloma: targeting the seed and the soil.
by: Edwards, C
Published: (2012)

Transdermal lovastatin enhances fracture repair in rats.
by: Gutierrez, G, et al.
Published: (2008)

EphB4 Expression in Osteoblasts is Regulated by Myeloma Cells and the Wnt Signaling Pathway.
by: Bates, A, et al.
Published: (2008)